De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alberta
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

• Adult patients with hepatocellular (HCC) carcinoma receiving liver transplant

Exclusion criteria:

• Patients less than 18 years of age